SciSparc Ltd. (NASDAQ:SPRC – Get Free Report) saw a large drop in short interest in the month of February. As of February 13th, there was short interest totaling 138,165 shares, a drop of 21.5% from the January 29th total of 176,031 shares. Based on an average daily volume of 171,035 shares, the days-to-cover ratio is presently 0.8 days. Currently, 3.9% of the shares of the company are sold short. Currently, 3.9% of the shares of the company are sold short. Based on an average daily volume of 171,035 shares, the days-to-cover ratio is presently 0.8 days.
SciSparc Price Performance
NASDAQ:SPRC opened at $0.56 on Monday. The stock has a 50-day simple moving average of $0.98 and a two-hundred day simple moving average of $2.42. SciSparc has a 52-week low of $0.49 and a 52-week high of $10.82.
SciSparc (NASDAQ:SPRC – Get Free Report) last posted its quarterly earnings data on Tuesday, November 18th. The company reported ($3.08) EPS for the quarter. The firm had revenue of $0.23 million during the quarter.
SciSparc Company Profile
SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.
The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.
Further Reading
- Five stocks we like better than SciSparc
- Silver Crossed $100: Is the $500 surge next? (Join us March 4)
- America’s 1776 happening again
- Unlocked: Elon Musk’s Next Big IPO
- Silver paying 20% dividend. Plus 68% share gains
- REVEALED: Something Big Happening Behind White House Doors
Receive News & Ratings for SciSparc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciSparc and related companies with MarketBeat.com's FREE daily email newsletter.
